Business Context and Reporting Period
This Form 6-K filing by Compugen Ltd. covers the period of February 2018, specifically dated February 6, 2018. The report serves to disclose specific scientific designations regarding the company's drug development pipeline.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of scientific nomenclature rather than a financial report.
Material Changes
There are no financial material changes reported. The primary disclosure concerns the identification of specific protein targets:
- ILDR2 protein: Designated as the novel immune checkpoint CGEN-15001T.
- Fusion protein: Composed of the extracellular domain of ILDR2 and an Fc domain, designated as CGEN-15001.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, outlook, risks, contingencies, or unusual items. The information is incorporated by reference into the Company's Registration Statement on Form F-3, File No. 333-213007.
Investor Verification Points
- Verify the clinical development status of CGEN-15001T and CGEN-15001 in subsequent filings.
- Review the referenced Form F-3 (File No. 333-213007) for broader context on the company's capitalization and offering details.
- Confirm the regulatory pathway for ILDR2 as an immune checkpoint inhibitor.